Animal-Free Dairy Proteins Market Outlook 2026–2036: Market Size, Growth Drivers, Key Players, Strategic Developments & Adoption Forecast for Precision-Fermented Whey, Casein and Lactoferrin, Finished Dairy Products, Fermentation Capacity and Regulatory Approval in the United States, Europe and Asia — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines how animal-free dairy proteins — whey, casein, lactoferrin and other milk proteins produced by precision fermentation in engineered microbes and sold as ingredients or in finished dairy products — will scale from a handful of plants and products into a supply source for the dairy and nutrition industries over the next ten years. The signals have turned from promise to production. Perfect Day, with more than USD 825 million raised, reports its current plant effectively sold out, with demand outpacing supply from sports, active and medical nutrition customers, and its joint venture with Zydus Lifesciences in Gujarat on track for initial operations in the second half of 2026 and a ramp-up through 2027, which the company expects to be profitable at launch. Remilk and Gad Dairies launched New Milk, a lactose-free milk made with recombinant beta-lactoglobulin, in Israeli cafés in November 2025 and retail in December, after Remilk paused its Danish plant in favour of co-packers. Casein, the protein that makes cheese, has reached the United States: New Culture and Those Vegan Cowboys hold self-affirmed GRAS status, Those Vegan Cowboys raised EUR 12.25 million in March 2026 including a record EUR 4 million crowdfunding from more than 1,850 investors and plans a EUR 100 million plant with a partner from 2028, and Standing Ovation closed a EUR 30 million Series B on 31 March 2026 led by Bpifrance and Crédit Mutuel Innovation with Danone Ventures and Bel Group. Verley raised USD 38 million in February 2026 and Vivici USD 38.4 million in 2025 before launching precision-fermented lactoferrin in the United States, and All G formed a lactoferrin joint venture with Savencia's Armor Protéines. Against this, Europe has approved no precision-fermented animal protein: Perfect Day's dossier was declared invalid in April 2024, Remilk withdrew, and the EU Biotech Act of December 2025 excluded novel foods from regulatory sandboxes, while Danone is closing its Bridgeton plant-based dairy alternatives plant. The brief maps the technology, its indicative market size and forecast, the factors behind its growth, the developments of the last 24 months, the key players operating in the space and the adoption trajectory to 2036.

It is a focused 108-page decision brief for dairy processors and cooperatives, ingredient and nutrition companies, consumer packaged goods groups, contract fermentation manufacturers, regulators and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which proteins and applications scale first, how cost, capacity and regulation set the pace, and who captures value as dairy proteins gain a second source.

Animal-free dairy proteins are made by inserting the gene for a milk protein into a yeast, fungus or bacterium, growing the microbe on sugars in fermentation tanks, and purifying the secreted protein. Beta-lactoglobulin, the main whey protein, was the first to scale: Perfect Day's GRAS notice was cleared in March 2020 and Remilk's in February 2023, and both sell into nutrition, dairy and ice-cream applications. Casein — the micellar protein that gives cheese its stretch and melt — is harder, because function depends on assembling several caseins into micelles with calcium and phosphate; New Culture, Those Vegan Cowboys and Standing Ovation have reached commercial entry with partners such as Westland Kaas, Hochland and Bel. Lactoferrin, a scarce, high-value protein for infant and immune nutrition, is now produced by Vivici and by All G with Armor Protéines. Products reach consumers either as ingredients in branded foods or as finished recombinant dairy such as Remilk's New Milk.

The commercial case rests on purity, functionality, security of supply and, increasingly, cost. Perfect Day reports that customers buy for supply security and functionality first, with sustainability a secondary benefit, and that demand exceeds its current plant; its Gujarat joint venture with Zydus Lifesciences is designed to be profitable at launch. Standing Ovation reports a 74% greenhouse gas reduction and up to three times less water than animal casein under an ISO-certified life-cycle assessment. Dairy incumbents have moved from observers to backers: Danone Ventures and Bel Group in Standing Ovation, Savencia's Armor Protéines in a joint venture with All G, Gad Dairies in a joint venture with Remilk, and dairy farmers and cheesemakers among Those Vegan Cowboys' crowdfunding investors.

The constraints are fermentation capacity and cost, regulation and the broader retreat from plant-based dairy. Large-scale, food-grade fermentation capacity is scarce, which is why Perfect Day built in India, Remilk paused its Danish plant for co-packers and Standing Ovation and Those Vegan Cowboys plan partner-built plants; the United States has cleared at least seven precision-fermented proteins while the European Union has authorised none, with Perfect Day's dossier declared invalid in April 2024, Remilk's withdrawn and the December 2025 Biotech Act excluding novel foods from sandboxes; and the plant-based dairy category is contracting, with Danone closing its Bridgeton alternatives plant. The decade's question is whether cost parity and a European approval arrive before investor patience in alternative proteins is exhausted.

The animal-free dairy proteins market — precision-fermented whey, casein, lactoferrin and other dairy protein ingredients, finished products made with them valued at ingredient level, and contract fermentation capacity dedicated to them, excluding plant-based dairy alternatives and conventional dairy proteins — is estimated at USD 0.25–0.4 billion in 2026, led by Perfect Day's and Remilk's recombinant whey, first casein sales from New Culture, Those Vegan Cowboys and Standing Ovation, lactoferrin from Vivici and All G, and the contract capacity of Olon, Zydus and co-packers in North America and Asia. Meticulous Next™ expects it to reach USD 4–6 billion by 2036, an indicative CAGR of 29–32%. Growth is driven by the Gujarat plant and successor facilities bringing recombinant whey toward cost parity from 2027, by casein entering commercial cheese in the United States from 2026–2028, by lactoferrin substituting scarce bovine supply in infant and adult nutrition, by dairy incumbents integrating fermented proteins into branded products, by a first EU authorisation around 2028–2029 and by Asian regulatory clearances. The forecast is sensitive to fermentation cost curves, EU decisions and the pace of dairy-industry adoption. The United States leads on clearances and demand; India leads on new capacity; Israel on finished recombinant dairy; France and the Netherlands on casein developers and dairy backers; Singapore and Australia on early Asian approvals.

The base case assumes the Gujarat plant ramps on schedule through 2027, casein reaches commercial cheese in the United States by 2028, whey cost parity by 2030 and a first EU authorisation by 2029. An accelerated case adds faster capacity additions, early EU approval under a reformed pathway and rapid dairy-incumbent integration, bringing the inflection to 2029 and lifting the 2036 value to the top of the range. A delayed case assumes capacity delays, prolonged EU refusal and continued alternative-protein funding drought, confining the market to US and Asian whey and lactoferrin for most of the horizon.

Growth drivers

• Sold-out capacity and demand exceeding supply at Perfect Day; Gujarat plant starting in the second half of 2026 with profitability expected at launch.
• Dairy incumbents as investors and partners: Danone Ventures and Bel in Standing Ovation, Savencia's Armor Protéines with All G, Gad Dairies with Remilk, Westland Kaas and Hochland with Those Vegan Cowboys.
• Casein cleared for sale in the United States under self-affirmed GRAS, opening cheese applications.
• Lactoferrin scarcity and price in infant and adult nutrition addressed by fermentation supply.

Enablers

• Food-grade fermentation capacity in India (Zydus), contract manufacturers (Olon) and co-packers in North America and Asia.
• Micelle assembly and functional casein science reaching commercial performance.
• US GRAS pathway and early Asian and Israeli clearances; Netherlands tasting approvals.
• Renewed capital: Standing Ovation EUR 30 million, Verley USD 38 million, Vivici USD 38.4 million, Those Vegan Cowboys EUR 12.25 million, Mars' precision fermentation investment.

Restraints and barriers

• No EU authorisation; Perfect Day dossier invalid (April 2024), Remilk withdrawn, Biotech Act excluding novel foods from sandboxes.
• Fermentation cost and capacity scarcity; Remilk's paused Danish plant.
• Plant-based dairy contraction and investor retreat from alternative proteins; Danone Bridgeton closure.
• Consumer labelling, dairy-industry opposition and naming rules.

Five converging forces will determine whether, and how fast, animal-free dairy proteins become a second source for the dairy industry: (1) fermentation capacity and cost curves; (2) regulatory clearance in the European Union and Asia; (3) casein functionality in cheese; (4) dairy-incumbent integration; and (5) nutrition demand for whey and lactoferrin. The brief assesses each force for direction, speed and confidence.

The key players operating in animal-free dairy proteins include Perfect Day, Inc., Zydus Lifesciences Limited, Remilk Ltd., Gad Dairies Ltd., Standing Ovation SAS, Those Vegan Cowboys B.V., New Culture, Inc., Verley SAS, Vivici B.V., All G Foods Pty Ltd, Armor Protéines SAS (Savencia Fromage & Dairy), Formo Bio GmbH, Bon Vivant SAS, Imagindairy Ltd., Change Foods, Inc., TurtleTree Labs Pte. Ltd., Fooditive B.V., De Novo Foodlabs, Olon S.p.A., Danone S.A. (Danone Ventures), Bel Group, Nestlé S.A., Unilever PLC, Mars, Incorporated, Fonterra Co-operative Group Limited, Arla Foods amba, FrieslandCampina N.V., Westland Kaas B.V., Hochland SE, Theo Müller Group, Temasek Holdings (Private) Limited, Horizons Ventures Limited, Bpifrance, Crédit Mutuel Innovation, Astanor Ventures, Seventure Partners, Invesdor, the Good Food Institute, the U.S. Food and Drug Administration, the European Food Safety Authority, the Singapore Food Agency and the Food Safety and Standards Authority of India. The brief profiles representative players in each archetype and assesses which are positioned to make fermentation a second source for dairy proteins.

The competitive landscape is forming around six archetypes. Recombinant whey producers at scale. Casein developers entering commercial cheese. Lactoferrin and specialised protein producers. Finished-product and brand developers. Dairy incumbents, CPG groups and contract manufacturers. Investors, industry bodies and regulators. Competitive intensity is moderate in 2026 and is expected to rise around cost parity and the first EU authorisation through 2030.

Where value migrates.

In 2026 value sits in recombinant whey sales from one sold-out plant, early casein and lactoferrin contracts and the capital funding new capacity. By 2030 it moves to multi-plant whey supply at cost parity, casein in commercial cheese, lactoferrin in nutrition and the first European authorisation. By 2036 it settles in scaled producers with partner plants, dairy incumbents that integrated fermented proteins, contract manufacturers and Asian production hubs. Producers without capacity partners or regulatory reach, and branded alternatives without ingredient economics, lose ground.

Capital has returned selectively to companies with partners and products: Standing Ovation's EUR 30 million with Danone Ventures and Bel, Verley's USD 38 million, Vivici's USD 38.4 million, Those Vegan Cowboys' EUR 12.25 million with a record crowdfunding, All G's joint venture with Savencia and Mars' precision fermentation investment, while the wider alternative-protein fermentation sector has seen funding fall and Perfect Day is expected to raise again. Commercial signals include a sold-out plant, finished recombinant milk at national retail and casein cleared for US sale. Patent and research activity centres on casein micelle assembly, high-yield secretion strains, downstream purification and lactoferrin glycosylation. The brief tracks four indicators: Gujarat plant start and ramp, first commercial cheese with fermented casein, the first EU authorisation and recombinant whey price against specialty dairy whey.

The United States leads on clearances and demand; India on new capacity; Israel on finished products; France and the Netherlands on casein developers and dairy backers; Singapore, the United Kingdom and Australia on early filings. Sports, active and medical nutrition, lactose-free milk, cheese and infant nutrition are the first applications.